Bavarian Nordic Secures USD 120 Million Contract for Smallpox and Mpox
BARDA Invests in Vaccine Manufacturing to Strengthen National Health Security
Contract Supports Replenishment of Depleted Inventory
The US Biomedical Advanced Research and Development Authority (BARDA) has awarded Bavarian Nordic a contract worth USD 120 million for the manufacturing of smallpox and mpox vaccines. The contract will support the production of new bulk vaccine to partially replenish the inventory used for the recent mpox outbreak.
Building on the trust and reliability established as a supplier of vaccines to the US Government for over a decade, Bavarian Nordic is committed to ensuring national health security. The contract award will allow the company to increase production of Jynneos, its smallpox and mpox vaccine, to meet the growing demand.
The commercial launch of Jynneos earlier this year marked a significant milestone in the fight against smallpox and mpox. The vaccine has proven to be effective in preventing severe illness and reducing the risk of transmission. By replenishing the national stockpile, BARDA is investing in the preparedness and response capabilities of the US Government.
With this contract, Bavarian Nordic continues to demonstrate its leadership in the development and production of essential vaccines for global health emergencies.
Comments